Feature | May 11, 2010| Dave Fornell

IVUS Developments Increase Diagnostic Value, Ease of Use

Boston Scientifics iColor overlay highlights the lumen and areas of plaque in a vessel.

As intravascular ultrasound (IVUS) becomes a more common tool in cath labs to assess lesions and stent treatments, new innovations loom on the horizon. These tools include forward-looking IVUS and a combination IVUS/balloon catheter.

Boston Scientific and Volcano Corp. are the only two vendors with U.S. Food and Drug Administration (FDA) clearance for IVUS systems. They will soon be joined by InfraReDx, which plans to release an IVUS
system later this year.

Angioplasty/IVUS Catheter
Volcano developed a combination IVUS/angioplasty balloon catheter to reduce the number of devices needed for a procedure, the time involved with exchanges, and the need to remove the IVUS catheters during treatment.

The Image Guided Therapy catheter will be released in Europe this year, and also is going through FDA review. The company expects to release it in the United States in 2011. It will be offered in multiple balloon sizes.

Forward-Looking IVUS
IVUS offers a cross-sectional view of a vessel, but is unable to visualize the area ahead of the catheter. Physicians have long been interested in a forward-looking IVUS system to help better assess and treat chronic total occlusions (CTOs). Such a system may also be useful in structural heart repair and cardiac ablations.

Volcano is developing two forward-looking (FL.IVUS) catheters, which it hopes to release in both the United States and Europe in 2011. A passive version for visualization only uses a transducer that rotates at an angle on the tip of the catheter. It creates a conical view of what lies ahead, said Frederick Wagner, Volcano’s senior marketing manager, strategic marketing. An active version will include visualization capability and a built-in radio frequency ablation tip to allow the catheter to tunnel through a CTO.

Plaque Characterization
IVUS echo returns can be processed to detect differences in the density of material off of which sound waves reflect. This can help identify different types of plaque. Volcano was the first to introduce this plaque characterization technology with Virtual Histology IVUS (VH IVUS). It color codes the makeup of plaque as fibrous, fibro-fatty, necrotic core and dense calcium.

Boston Scientific introduced iMap, its version of plaque characterization, in the fall of 2009. It uses a similar color-coding system. The tool is available overseas, but is still under FDA review.

“We, as well as Volcano, are trying to take the ambiguity out of a gray-scale image,” said Jeff Bennett, imaging group marketing manager for Boston Scientific. “Tissue characterization is not a vulnerable plaque finder by itself, you need other modalities.”

Identifying Vulnerable Plaque
A key research focus for IVUS is to help identify lipid-core vulnerable plaques, which are the suspected cause of most heart attacks.

“A lot of the events being blamed on stents are actually caused by lipid-core plaques at the end of the stent,” said James E. Muller, M.D., founder and CEO of InfraReDx. He said dilatation and stenting of a large lipid-core stenosis might cause emboli responsible for the “no-flow” phenomenon and heart attacks that complicate stenting.

Dr. Muller said the InfraReDx LipidScan uses intravascular near-infrared spectroscopy (NIRS), which is more precise in determining the chemical makeup of plaque than sound waves. However, spectroscopy does not provide an image.

The company plans to launch its LipiScan IVUS system, which combines IVUS and NIRS, in the United States by late 2010. The system will incorporate grayscale IVUS with a circle around the edge of the image displaying a color-code of high-lipid plaque areas. Dr. Muller said the system will make it easier to pinpoint and visualize different types of plaque. It will initially be used in efforts to increase the safety of stenting, but in the future he said it might be used to identify vulnerable plaques so they can be treated before causing a second heart attack.

New IVUS Catheters
IVUS catheters come in two forms: rotational and digital. Rotational catheters rapidly spin a tiny transducer to image the entire cross section of the vessel per rotation. Digital catheters use a phased array of transducers mounted in fixed positions, creating a ring with each transducer imaging a different section of the vessel.

Rotational IVUS offers more detail and better resolution, Wagner said. However, these catheters require a saline flush to remove air inside the catheter for full fluid contact for the best imaging.
Digital IVUS is easier to use because it does not require a saline flush. It also provides enhanced features, such as plaque characterization and blood flow imaging, Wagner said.

“With Volcano’s digital IVUS, you gain the advantages of speed and ease of use compared with rotational, while giving up a little in image resolution. Additionally, you have the option for plaque characterization and blood flow imaging,” Wagner explained.

In 2009, Boston released its iCross catheter, which has a hydrophilic coating. Bench tests showed a 28 percent improvement in delivery.

In mid-2010, Volcano said it is releasing the Eagle Eye Platinum catheter, which has improved deliverability and additional radiopaque markers for better visualization and length estimations under angiography. It offers a hydrophilic coating, lower profile, softer tip and smoother transitions. The catheter already has FDA clearance.

FFR Integration
In addition to intravascular imaging, Volcano’s system also integrates fractional flow reserve (FFR) without the need for a separate FFR system. Volcano and St. Jude Medical are the only two device vendors with FDA-cleared FFR systems.

Related Content

News | Peripheral Arterial Disease (PAD)| August 22, 2016
Avinger Inc. recently announced the closing of its previously announced public offering of 9,857,800 shares of Avinger’...
SJM, OCT, Optical coherence tomography, Bioresorbable stent, BVS

An optical coherence tomography (OCT) image of an Absorb bioresorbable stent. The stent struts are clear, allowing light to pass through, and in some cases magnifying the light that passes through under each strut. Image courtesy of St. Jude Medical.

Feature | Stents Bioresorbable| July 21, 2016 | Alphonse Ambrosia, D.O.
Some have labeled bioresorbable scaffolds (BRS), also known as bioresorbable stents, as the fourth evolution of inter
3-D OCT

A 3-D OCT rendering of a stented vessel segment created on St. Jude Medical's Ilumien Optis OCT system. 

Feature | Angiography| July 15, 2016 | Dave Fornell
While angiographic X-ray fluoroscopy systems are the workhorse for transcatheter cardiovascular interventional proced
IVPA, intravascular photoacoustic imaging, fatty arteries, Purdue, Shanghai

IVPA/IVUS imaging of a perfused fresh human right coronary artery dissected from an explanted heart. (A) IVPA image. (B) IVUS image. (C) Merged IVPA/IVUS image. The 1 mm scale bar applies to all panels.

News | Intravascular Imaging| May 25, 2016
A new imaging system known as intravascular photoacoustic (IVPA) imaging that produces three-dimensional images of the...
PCI, OFDI, OCT, optical coherence tomography, optimal frequency domain imaging, EuroPCR 2016 study
News | Intravascular Imaging| May 20, 2016
Using optimal frequency domain imaging (OFDI) to guide percutaneous coronary intervention (PCI) with second-generation...
vulnerable plaques, OCT, IVUS, catheter, combination, NIBIB study

The dual catheter OCT-IVUS imaging device can be inserted into an artery to simultaneously capture an infrared image of the arterial wall (OCT, at left) and an ultrasound image (IVUS, right) that doctors use to determine the potential that a plaque is susceptible to rupture that could cause a heart attack or stroke.

News | Intravascular Imaging| May 12, 2016
May 12, 2016 — Collaboration between two National Institute of Biomedical Imaging and Bioengineering (NIBIB)-funded l
Neovasc, Tiara, transcatheter mitral valve, TMVR

Transcatheter mitral valve technology was among the most popular content on the DAIC website in 2015. Pictured is the Neovasc Tiara transcatheter mitral valve, which is currently in clinical trials.

Feature | March 22, 2016 | Dave Fornell
DAIC readers chose the following stories as the most popular content in 2015, based on website analytics.
Avinger, Pantheris lumivascular atherectomy system, PAD treatment, peripheral artery disease, FDA clearance
Technology | Atherectomy Devices| March 03, 2016
Avinger Inc. announced the company has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for...
Philips, Volcano, IVUS, vein obstruction diagnosis, multiplanar X-ray venography, VIDIO study
News | Intra-Vascular Ultrasound (IVUS)| February 29, 2016
Philips announced that new clinical trial data demonstrates the benefits of its intravascular ultrasound (IVUS)...
Overlay Init